- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07294209
Nízkodávkový tenektepláz pro léčbu akutní ischemické cévní mozkové příhody u stárnoucích pacientů (DATE-AGING)
Efektivita a bezpečnost nízkodávkového tenekteplázy při léčbě akutní ischemické cévní mozkové příhody u stárnoucích pacientů: prospektivní, multicentrická, randomizovaná kontrolovaná studie
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
Přehled studie
Postavení
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 4
Kontakty a umístění
Studijní místa
-
-
-
Anshan, Čína
- Anshan Changda Hospital
-
Anyang, Čína
- Anyang People's Hospital
-
Anyang, Čína
- Huaxian People's Hospital of Henan
-
Baoshan, Čína
- Baoshan People's Hospital
-
Bijie, Čína
- People's Hospital of Zhijin County
-
Chongqing, Čína
- Chongqing University Three Gorges Hospital
-
Chongqing, Čína
- Chongqing University Jiangjin Hospital
-
Chongqing, Čína
- Bishan Hospital
-
Chongqing, Čína
- Chongqing Emergency Medical Center
-
Chongqing, Čína
- Chongqing University Fuling Hospital
-
Chongqing, Čína
- Dianjiang People's Hospital OF Chongqing
-
Chongqing, Čína
- People's Hospital Of Xiushan County
-
Chongqing, Čína
- The People's Hospital of Dazu Chongqing
-
Chongqing, Čína
- The People's Hospital of HeChuan, Chongqing
-
Chongqing, Čína
- The People's Hospital of Rongchang Chongqing
-
Chongqing, Čína
- The People's Hospital of Tongnan District Chongqing City
-
Chongqing, Čína
- The Seventh People's Hospital of Chongqing
-
Chongqing, Čína
- Tongliang Hospital
-
Chongqing, Čína
- Yunyang County People's Hospital
-
Dali, Čína
- Dali Bai Autonomous Prefecture People's Hospital
-
Dazhou, Čína
- Dazhou Central Hospital
-
Deyang, Čína
- The People's Hospital of Zhongjiang
-
Guang’an, Čína
- Guang an People's Hospital
-
Guiyang, Čína
- Guizhou Provincial People's Hospital
-
Guiyang, Čína
- The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
-
Ha’erbin, Čína
- The First Affiliated Hospital of Harbin Medical University
-
Hebi, Čína
- Xunxian People's Hospital
-
Heyuan, Čína
- Heyuan People's Hospital
-
Huanggang, Čína
- Qichun People's Hosiptal
-
Jianyang, Čína
- The People's Hospital Of Jianyang City
-
Laixi, Čína
- Laixi People's Hospital
-
Leshan, Čína
- People's Hospital of Leshan
-
Leshan, Čína
- Leshan Geriatric Specialized Hospital
-
Luoyang, Čína
- Luoyang Mengjin People's Hospital
-
Nanchong, Čína
- Nanbu People's Hospital
-
Pujiang, Čína
- Puyang People's Hospital
-
Pujiang, Čína
- The People's Hospital of Nan Le Xian
-
Shangqiu, Čína
- People's Hospital of Ningling County
-
Shangqiu, Čína
- The First People's Hospital of Shangqiu
-
Shaoyang, Čína
- The First People ' S Hospital of Shao Yang
-
Shijiazhuang, Čína
- The People's Hospital of Gaocheng
-
Wuhan, Čína
- Wuhan Puren Hospital
-
Xiangyang, Čína
- Xiangyang NO.1 People's Hospital
-
Yibin, Čína
- The second people's hospital of Yibin
-
Zhumadian, Čína
- Zhumadian Central Hospital
-
Zhuzhou, Čína
- Zhuzhou Central Hospital
-
Zigong, Čína
- Zigong Third People's Hospital
-
Ziyang, Čína
- Ziyang Central Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Čína, 400038
- Southwest Hospital, Chongqing, China
-
-
Heilongjiang
-
Harbin, Heilongjiang, Čína, 150200
- Wuchang People's Hospital
-
-
Henan
-
Zhoukou, Henan, Čína, 466300
- Shenqiu County People's Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age ≥ 70 years;
- Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
- Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
- Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
- Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
- Informed consent from the patient or surrogate.
Exclusion Criteria:
-
Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);
-
Acute bleeding diathesis or allergy to tenecteplase, including but not limited to
- Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
- Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
- Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
- Platelet count of below 100×10^9/ L
- Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
- Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
- Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
- Neoplasm with increased haemorrhagic risk
- Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
- History of significant trauma or major surgery within the past 3 months.
- Any known disorder associated with a significant increased risk of bleeding
-
Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);
-
Blood glucose <2.8 mmol/L or >22.22 mmol/L;
-
After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;
-
Seizure at stroke onset;
-
Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;
-
Participation in other clinical trials within 3 months prior to screening;
-
Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Low-Dose Tenecteplase
0.175mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient. |
|
Aktivní komparátor: Standard-Dose Tenecteplase
0.25mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Časové okno: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
Časové okno: At 24 hours
|
National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. |
At 24 hours
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Časové okno: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Distribution of Modified Rankin Scale (mRS)
Časové okno: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Percentage of Participants With Barthel Index Score ≥95
Časové okno: up to 90 days
|
The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome. |
up to 90 days
|
|
EQ-5D-5L score
Časové okno: At Day 90±7 days
|
Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life) |
At Day 90±7 days
|
|
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
Časové okno: up to 36 hours
|
sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline. |
up to 36 hours
|
|
All-cause mortality
Časové okno: up to 90 days
|
All-cause mortality at 90 days |
up to 90 days
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Časové okno: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- 2025IITDA10
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .